A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

Post time 1 hour(s) ago

journal：Molecular Cancer Therapeutics

Authors：Matteo Duca; Darren Wan-Teck Lim; Vivek Subbiah; Shunji Takahashi; John Sarantopoulos; Andrea Varga; Joseph A. D'Alessio; Tinya Abrams; Qing Sheng; Eugene Youchin Tan; Maria Santos Rosa; Juan Gonzalez-Maffe; Janna Sand-Dejmek; Claire Fabre; Miguel Martin

Published date：2022-4-1

DOI：10.1158/1535-7163.mct-21-0652

PDF link：https://aacrjournals.org/mct/article-pdf/21/4/625/3107827/625.pdf

Article link：https://doi.org/10.1158/1535-7163.mct-21-0652

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 1 hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

Best Answer

Viewed forums

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors Copy